Xynomic Pharmaceuticals Holdings, Inc. (XYNO): Price and Financial Metrics

Xynomic Pharmaceuticals Holdings, Inc. (XYNO): $2.22

0.06 (+2.78%)

POWR Rating

Component Grades













Add XYNO to Watchlist
Sign Up

Industry: Biotech



in industry

XYNO Stock Price Chart Interactive Chart >

Price chart for XYNO

XYNO Price/Volume Stats

Current price $2.22 52-week high $3.84
Prev. close $2.16 52-week low $0.20
Day low $2.22 Volume 100
Day high $2.22 Avg. volume 875
50-day MA $2.05 Dividend yield N/A
200-day MA $0.00 Market Cap 102.73M

Xynomic Pharmaceuticals Holdings, Inc. (XYNO) Company Bio

Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.

XYNO Latest News Stream

Event/Time News Detail
Loading, please wait...

XYNO Latest Social Stream

Loading social stream, please wait...

View Full XYNO Social Stream

XYNO Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2022 N/A
2021 0.00%
2020 -51.57%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6067 seconds.